Literature DB >> 21087987

Angiolipoma of the female breast: clinicomorphological correlation of 52 cases.

Oleksandr N Kryvenko1, Dhananjay A Chitale, Eve M VanEgmond, Nilesh S Gupta, Daniel Schultz, Min W Lee.   

Abstract

The authors analyzed 52 cases of female breast angiolipoma (AL). Age distribution was 25 to 80 years of age (56.81 ± 12.78). Most cases showed vascularity below 50%, and 14 cases had vascularity >50%. Cellular and low-vascularity ALs had different clinical and radiological presentations. The mean size was 7.00 ± 3.62 mm for cellular ALs and 19.61 ± 7.58 mm for low-vascularity ALs. In any paucicellular area, the authors could identify a cluster of at least 3 interconnected vessels. The endothelium was mostly flat with uniform, hyperchromatic nuclei, and mitoses and nucleoli were absent. Fibrin thrombi in proliferating capillaries were noted in 96% of cases. Low-vascularity AL can be reliably distinguished on needle core biopsy from other lipomatous and vascular tumors of the breast. Tortuosity and proliferation of capillaries with at least 3 interconnected capillary channels in 1 focus with associated fibrin thrombi constitute a very strong clue for the diagnosis of AL on a breast needle core biopsy. Definite diagnosis of cellular AL is not always feasible because of rare cases with mitotic activity and cellular atypia. Excision is often recommended for cellular AL.

Entities:  

Mesh:

Year:  2010        PMID: 21087987     DOI: 10.1177/1066896910385679

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  2 in total

1.  Four cases of echogenic breast lesions: a case series and review.

Authors:  Lin Wah Goh; Su Lin Jill Wong; Puay Hoon Tan
Journal:  Singapore Med J       Date:  2016-02-19       Impact factor: 1.858

2.  Anastomosing Hemangioma of the Breast: An Unusual Case at an Unusual Site.

Authors:  Michelle S Lin; Thu Ngo; Mary R Schwartz; Rajul R Mehta; Alberto G Ayala; Jae Y Ro
Journal:  J Breast Cancer       Date:  2020-02-17       Impact factor: 3.588

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.